| Kristy Whitman, MD | |
|
694 Good Dr, Suite 11, Lancaster, PA 17601-2433 | |
| (717) 544-3737 | |
| (717) 544-3739 |
| Full Name | Kristy Whitman |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 19 Years |
| Location | 694 Good Dr, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316091739 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD437308 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Hospital | 1254240039 | 408 |
News Archive
Cancerous tumors are made up of many more components than just malignant cells from the tissue of origin. Immune cells can be recruited to the tumor site and form what is known as the tumor microenvironment.
A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).
Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.
A joint team of researchers from Radiation Oncology at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center, Dartmouth Engineering, and Dartmouth-Hitchcock's Department of Surgery have developed a method to convert a standard linear accelerator, used for delivery of radiation therapy cancer treatment, to a FLASH ultra-high-dose rate radiation therapy beam.
› Verified 3 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720430812 PECOS PAC ID: 1254240039 Enrollment ID: O20040414000606 |
News Archive
Cancerous tumors are made up of many more components than just malignant cells from the tissue of origin. Immune cells can be recruited to the tumor site and form what is known as the tumor microenvironment.
A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).
Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.
A joint team of researchers from Radiation Oncology at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center, Dartmouth Engineering, and Dartmouth-Hitchcock's Department of Surgery have developed a method to convert a standard linear accelerator, used for delivery of radiation therapy cancer treatment, to a FLASH ultra-high-dose rate radiation therapy beam.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristy Whitman, MD 694 Good Dr, Suite 11, Lancaster, PA 17601-2433 Ph: (717) 544-3737 | Kristy Whitman, MD 694 Good Dr, Suite 11, Lancaster, PA 17601-2433 Ph: (717) 544-3737 |
News Archive
Cancerous tumors are made up of many more components than just malignant cells from the tissue of origin. Immune cells can be recruited to the tumor site and form what is known as the tumor microenvironment.
A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).
Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.
A joint team of researchers from Radiation Oncology at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center, Dartmouth Engineering, and Dartmouth-Hitchcock's Department of Surgery have developed a method to convert a standard linear accelerator, used for delivery of radiation therapy cancer treatment, to a FLASH ultra-high-dose rate radiation therapy beam.
› Verified 3 days ago
Dr. Jon Michael Katz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 694 Good Dr Ste 200, Lancaster, PA 17601 Phone: 717-544-3514 Fax: 717-544-3515 | |
George J Olt, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2102 Harrisburg Pike, Suite 102, Lancaster, PA 17601 Phone: 717-544-0340 | |
Dr. John Joseph Eichenlaub, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2128 Embassy Dr, Lancaster, PA 17603 Phone: 717-509-5090 Fax: 717-509-5078 | |
Pamela Martin Hershner, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 694 Good Dr, Lancaster, PA 17601 Phone: 717-544-3737 | |
Dr. Ani Elise Stull, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 694 Good Drive, Lancaster, PA 17601 Phone: 717-397-8177 | |
Katherine Hicks-courant, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2102 Harrisburg Pike, Lancaster, PA 17601 Phone: 717-544-3968 Fax: 717-544-9401 | |
Dr. Bryon N Jacoby, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 694 Good Dr Ste 200, Lancaster, PA 17601 Phone: 717-544-3514 Fax: 717-544-3515 |